A strategic financial analysis of iPSC-based manufacturing
vs. autologous models
Author: Astrid Van Damme, PhD – Head of Project Management
Highlights
- Industrialized iPSC manufacturing is emerging as the decisive factor in making cell therapies scalable, affordable, and commercially viable.
- Standardized, off‑the‑shelf production models remove the barriers of autologous manufacturing and enable global deployment.
- Real‑world analysis: based on the Echo™ NK platform, the study quantifies up to a 95% reduction in COGS through industrialized iPSC manufacturing.
- Batch yield and facility utilization are identified as the dominant economic levers determining long‑term sustainability and margin expansion.
- The cost structure shifts from labor‑driven to materials‑driven, enabling predictable, reproducible, and scalable economics.
- Standardization delivers not only efficiency but also market access and reimbursement viability—turning scalability into a strategic advantage.
Access the full paper
including detailed cost modeling, Echo™‑NK case data, and economic benchmarks.